Medtronic and IRS Dispute Resolution Provides Guidelines on Transfer Pricing Agreements

Jun 24, 2016

Reading Time : 1 min

Medtronic’s Puerto Rican affiliate, Medtronic Puerto Rico Operations Co. (MPROC), and Medtronic entered into four separate intercompany agreements covering Medtronic’s sales of components to MPROC and MPROC’s sale of finished products to Medtronic. Medtronic priced each of the four agreements separately, such that MPROC was treated as “a full-fledged entrepreneurial licensee responsible for its own success.” Despite these agreements, the IRS treated MPROC as a contract manufacturer, rather than an autonomous manufacturing licensee of medical devices.

The IRS argued that MPROC posted “outsize profits” in tax years 2005 and 2006, leading to “absurd results,” such as returns on assets of 211 percent and 301 percent, thereby making MPROC vastly more profitable than Medtronic and Medtronic’s competitors. The court found, however, that the IRS’ treatment of MPROC was fatally flawed in that it treated MPROC as a mere assembly operation, rather than a company critical to the quality of the products. The court cited several factors as indicative of the character of MPROC, including the facilities being registered with the United States Food and Drug Administration responsible for manufacturing medical devices for treatment of cardiac and neurological conditions and employing 2,300 workers—including engineers—in three locations.

While similar cases will be highly fact-specific, this case is instructive of the structure and circumstances necessary to uphold intercompany transfer pricing agreements.

Medtronic, Inc. v. Commissioner, T.C., No. 6944-11, T.C. Memo. 2016-112, June 9, 2016.

Share This Insight

Previous Entries

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

IP Newsflash

December 5, 2025

District courts are split on whether a complaint can provide the required knowledge for post-suit indirect and willful infringement in that same lawsuit. Chief Judge Connolly in the District of Delaware recently confirmed that, consistent with his prior opinions, the complaint cannot serve as the basis for knowledge for either a claim of post-suit indirect infringement or a demand for willfulness-based enhanced damages in that lawsuit.

...

Read More

IP Newsflash

December 3, 2025

The Federal Circuit recently held that a patentee acted as its own lexicographer to define a claim term even though it did not explicitly define the term. Rather, because the patentee consistently and clearly used two terms interchangeably to describe the same structural feature and did so in all of the embodiments in which the feature appeared, the patentee impliedly gave the term its own, unique definition.

...

Read More

IP Newsflash

December 2, 2025

The Federal Circuit recently held an asserted patent was not entitled to its priority date because the priority application lacked written description support for the asserted claims. In so doing, the court explained that broad disclosures that do not provide reasonably specific support for narrower claims do not meet the written description requirement. The court also considered whether the inventor’s testimony showed they possessed the full scope of the claimed genus at the priority date or whether it was more likely the inventors first became aware of the claimed embodiments from public disclosures of the accused product.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.